EVO:NSD-Evotec SE ADR (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 4.6

Change

+0.12 (+2.68)%

Market Cap

USD 1.44B

Volume

0.03M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-24 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
VTRS Viatris Inc

+0.35 (+3.11%)

USD 14.20B
NBIX Neurocrine Biosciences Inc

+1.38 (+1.20%)

USD 11.95B
ITCI Intracellular Th

-1.16 (-1.56%)

USD 8.20B
LNTH Lantheus Holdings Inc

-3.52 (-3.26%)

USD 7.64B
ALKS Alkermes Plc

+0.74 (+2.80%)

USD 4.47B
ALVO Alvotech

+0.13 (+1.16%)

USD 3.39B
HCM HUTCHMED DRC

+0.93 (+5.32%)

USD 2.97B
AMPH Amphastar P

+1.16 (+2.48%)

USD 2.29B
KNSA Kiniksa Pharmaceuticals Ltd

-0.14 (-0.58%)

USD 1.83B
SUPN Supernus Pharmaceuticals Inc

+0.83 (+2.77%)

USD 1.77B

ETFs Containing EVO

EXV9:XETRA iShares (DE) I - iShares .. 14.55 % 0.00 %

+0.22 (+1.60%)

USD 0.10B
ODDS Pacer BlueStar Digital En.. 6.82 % 0.00 %

+0.37 (+1.60%)

USD 0.95M
BETS:XETRA 6.59 % 0.00 %

N/A

N/A
BETZ Roundhill Sports Betting .. 5.80 % 0.00 %

+0.16 (+1.60%)

USD 0.08B
PCIG Litman Gregory Funds Trus.. 4.62 % 0.00 %

+0.16 (+1.60%)

N/A
DXW:CA Dynamic Active Internatio.. 4.11 % 0.00 %

+0.51 (+1.60%)

CAD 0.02B
XWD1:LSE Xtrackers MSCI World Swap.. 1.75 % 0.00 %

+0.11 (+1.60%)

N/A
BJK VanEck Gaming ETF 0.00 % 0.66 %

+1.51 (+1.60%)

N/A
EWD iShares MSCI Sweden ETF 0.00 % 0.53 %

+1.03 (+1.60%)

N/A
IESZ:LSE 0.00 % 0.00 %

N/A

N/A
OMXS:LSE iShares OMX Stockholm Cap.. 0.00 % 0.00 %

+11.00 (+1.60%)

N/A
DXSN:F Xtrackers - ShortDAX Dail.. 0.00 % 0.00 %

-0.21 (1.60%)

N/A
DXSP:F Xtrackers - Euro Stoxx 50.. 0.00 % 0.00 %

-0.17 (1.60%)

N/A
EL4C:F Deka STOXX Europe Strong .. 0.00 % 0.00 %

N/A

N/A
EXV9:F iShares (DE) I - iShares .. 0.00 % 0.00 %

N/A

N/A
XDN0:F db x-trackers MSCI Nordic.. 0.00 % 0.00 %

N/A

USD 1.11B
EL4C:XETRA Deka STOXX Europe Strong .. 0.00 % 0.00 %

+1.19 (+1.60%)

USD 0.29B
OM3X:XETRA iShares OMX Stockholm Cap.. 0.00 % 0.00 %

+1.46 (+1.60%)

USD 1.31B
XDN0:XETRA db x-trackers MSCI Nordic.. 0.00 % 0.00 %

+0.22 (+1.60%)

USD 1.03B
XNZN:XETRA Xtrackers Nordic Net Zero.. 0.00 % 0.00 %

+0.17 (+1.60%)

USD 0.21B
XDN0:SW Xtrackers MSCI Nordic UCI.. 0.00 % 0.00 %

+0.26 (+1.60%)

USD 1.09B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -60.78% 18% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.78% 18% F 8% B-
Trailing 12 Months  
Capital Gain -58.33% 31% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.33% 31% F 17% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -12.45% 45% F 24% F
Dividend Return -12.45% 43% F 24% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 22.85% 88% B+ 73% C
Risk Adjusted Return -54.48% 35% F 19% F
Market Capitalization 1.44B 85% B 76% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector